SEARCH

SEARCH BY CITATION

References

  • 1
    Bacus SS, Zelnick CR, Plowman G, Yarden Y. Expression of the erbB-2 family of growth factor receptors and their li-gands in breast cancers. Implication for tumor biology and clinical behavior. Am J Clin Pathol 1994; 102(Suppl 1): S1324.
  • 2
    De Potter CR. The neu-Oncogene: More than a prognostic indicator? Hum Pathol 1994; 25: 12648.
  • 3
    Monk BJ, Chapman JA, Johnson GA, Brightman BK, Wilczyn-ski SP, Schell MJ, et al. Correlation of C-myc and HER-2/ neu amplification and expression with histopathologic variables in uterine corpus cancer. Am J Obstet Gynecol 1994; 171: 11938.
  • 4
    Neilsen AL, Nyholm HC. p53 Protein and c-erbB-2 protein (p185) expression in endometrial adenocarcinoma of the endometrioid type. An immunohistochemical examination on paraffin sections. Am J Clin Pathol 1994; 102: 769.
  • 5
    Reinartz JJ, George E, Lindgren F, Niehans GA. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum Pathol 1994; 25: 107583.
  • 6
    Brumm C, Riviere A, Wilckens C, Loning T. Immunohistochemical investigation and northern blot analysis of c-erbB-2 expression in normal, premalignant and malignant tissues of the corpus and cervix uteri. Virch Arch A Pathol Anat Histopathol 1990; 417: 47784.
  • 7
    Kihana T, Tsuda H, Teshima S, Nomoto K, Tsugane S, So-noda T, et al. Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix. Cancer 1994; 73: 14853.
  • 8
    Hale RJ, Buckley CH, Fox H, Williams J. Prognostic value of c-erbB-2 expression in uterine cervical carcinoma. J Clin Pathol 1992; 45: 5946.
  • 9
    Oka K, Nakano T, Arai T. c-erbB-2 Oncoprotein expression is associated with poor prognosis in squamous cell carcinoma of the cervix. Cancer 1994; 73: 66471.
  • 10
    Sato S, Ito K, Ozawa N, Yajima A, Sasano H. Expression of c-myc, epidermal growth factor receptor and c-erbB-2 in human endometrial carcinoma and cervical adenocarcino-mas. Tohoku J Exp Med 1991; 165: 13745.
  • 11
    van Dam PA, Lowe DG, Watson JV, James M, Chard T, Hudson CN, et al. Multiparameter flow-cytometric quantitation of epidermal growth factor receptor and c-erbB-2 oncoprotein in normal and neoplastic tissues of the female genital tract. Gynecol Oncol 1991; 42: 25664.
  • 12
    Zhang X, Silva E, Gershenson D, Hung MC. Amplification and rearrangement of c-erb B proto-oncogenes in cancer of human female genital tract. Oncogene 1989; 4: 9859.
  • 13
    Kohler M, Bauknecht T, Grimm M, Birmelin G, Kommoss F, Wagner E. Epidermal growth factor receptor and transforming growth factor alpha expression in human ovarian carcinomas. Eur J Cancer 1992; 28A: 14327.
  • 14
    Nguyen PL, Swanson PE, Waclaw J, Aeppli DM, Zhang G, Singleton TP, et al. Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. Am J Clin Pathol 1994; 101: 16676.
  • 15
    Sorscher SM, Russack V, Graziano S, Cagle M, Feramisco JR, Green MR. Immunohistochemical evaluation of E-cadherin and epidermal growth factor receptor in non-small cell lung cancer. Mod Pathol 1995; 8: 4505.
  • 16
    Singleton TP, Niehans GA, Gu F, Litz CE, Hagen K, Qiu Q, et al. Detection of c-erb B-2 activation in paraffin embedded tissue by immunohistochemistry. Hum Pathol 1992; 23: 114150.
  • 17
    Norris HJ, Taylor HB. Mesenchymal tumors of the uterus III. A clinical and pathologic study of 31 carcinosarcomas. Cancer 1966; 19: 145965.
  • 18
    Norris HJ, Roth E, Taylor HB. Mesenchymal tumors of the uterus II. Clinical and pathologic study of 31 mixed meso-dermal tumors. Obstet Gynecol 1966; 28: 5763.
  • 19
    Chuang JT, Van Velden JJ, Graham JB. Carcinosarcoma and malignant mixed mesodermal tumors of the uterine corpus. Obstet Gynecol 1970; 35: 76980.
  • 20
    Williamson EO, Christopherson WM. Malignant mixed mülle-rian tumors of the uterus. Obstet Gynecol 1972; 29: 58592.
  • 21
    Barwick KW, Livolsi VA. Malignant mixed müllerian tumors of the uterus. A clinicopathologic assessment of 34 cases. Am J Surg Pathol 1979; 3: 12535.
  • 22
    Macasaet MM, Waxman M, Fruchter RG, Boyce J, Hong P, Nicastri AD, et al. Prognostic factors in malignant mesoder-mal (müllerian) mixed tumors of the uterus. Gynecol Oncol 1985; 20: 3242.
  • 23
    Gagne E, Tetu B, Blondeau L, Raymond PE, Blais R. Morphologic prognostic factors of malignant mixed müllerian tumor of the uterus: A clinicopathologic study of 58 cases. Mod Pathol 1989; 2: 4338.
  • 24
    Dinh TV, Slavin RE, Bhagavan BS, Hannigan EV, Tiamson E, Yandell RB. Mixed Müllerian tumors of the uterus: A clini-copathologic study. Obstet Gynecol 1989; 4: 38892.
  • 25
    Gallup DG, Gable DS, Talledo E, Otken LB. A clinical-pathologic study of mixed Müllerian tumors of the uterus over a 16-year period-The Medical College of Georgia experience. Am J Obstet Gynecol 1989; 161: 5339.
  • 26
    Nielsen S, Podratz KC, Scheithauer BW, O'Brien PC. Clinico-pathologic analysis of uterine malignant mixed müllerian tumors. Gynecol Oncol 1989; 34: 3728.
  • 27
    Silverberg SG, Major FJ, Blessing BF, Fetter B, Askin FB, Liao SY, et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A gynecologic oncology group pathologic study of 203 cases. Int J Gynecol Pathol 1990; 9: 119.
  • 28
    Schweizer W, Demopoulous R, Beller U, Dubin N. Prognostic factors for malignant mixed müllerian tumors of the uterus. Int J Gynecol Pathol 1990; 9: 12936.
  • 29
    Larson B, Silversward C, Nilsson B, Pettersson F. Mixed müllerian tumors of the uterus-prognostic factors: a clinical and histopathologic study of 147 cases. Radiother Oncol 1990; 17: 12332.
  • 30
    Dehner LP, Norris HJ, Taylor HB. Carcinosarcomas and mixed mesodermal tumors of the ovary. Cancer 1971; 27: 20716.
  • 31
    Barwick KW, Livolsi VA. Malignant mixed mesodermal tumors of the ovary: a clinicopathologic assessment of 12 cases. Am J Surg Pathol 1980; 4: 3742.
  • 32
    Terada KY, Johnson TL, Hopkins M, Roberts JA. Clinicopathologic features of ovarian mixed mesodermal tumors and carcinosarcomas. Gynecol Oncol 1989; 32: 22832.
  • 33
    Barakat RR, Rubin SC, Wong G, Saigo PE, Markman M, Hos-kins WJ. Mixed mesodermal tumor of the ovary: analysis of prognostic factors in 31 cases. Obstet Gynecol 1992; 80: 6604.
  • 34
    Zalaudek C, Norris HJ. Mesenchymal tumors of the uterus. In: KurmanRJ, editor. Blaustein's pathology of the female genital tract. 4th edition. New York: Springer-Verlag, 1994: 487528.
  • 35
    Geisinger GR, Dabbs DJ, Marshall RB. Malignant mixed müllerian tumors. An ultrastructural and immunohistochemical analysis with histogenetic considerations. Cancer 1987; 59: 178190.
  • 36
    Chung MT, Mukai K, Teshima S, Kishi K, Shimosato Y. Expression of various antigens by different components of uterine mixed müllerian tumors. An immunohistochemical study. Acta Pathol Jpn 1988; 38: 3545.
  • 37
    Bitterman P, Chun B, Kurman RJ. The significance of epithelial differentiation in mixed mesodermal tumors of the uterus. A clinicopathologic and immunohistochemical study. Am J Surg Pathol 1990; 14: 31728.
  • 38
    Meis J, Lawrence D. The immunohistochemical profile of malignant mixed müllerian tumor. Overlap with endome-trial carcinoma. Am J Clin Pathol 1990; 94: 17.
  • 39
    Costa MJ, Khan R, Judd R. Carcinosarcoma (malignant mixed müllerian [mesodermal] tumor) of the uterus and ovary. Correlation of clinical, pathologic and immunohistochemical features in 29 cases. Arch Pathol Lab Med 1991; 115: 58390.
  • 40
    George E, Manivel JC, Dehner LP, Wick MR. Malignant mixed müllerian tumors: an immunohistochemical study of 47 cases with histogenetic considerations and clinical correlation. Hum Pathol 1991; 22: 21523.
  • 41
    De Brito PA, Silverberg SG, Orenstein JM. Carcinosarcoma (malignant mixed müllerian (mesodermal) tumor of the female genital tract. Immunohistochemical and ultrastructural analysis of 28 cases. Hum Pathol 1992; 24: 13242.
  • 42
    Sreenan JJ, Hart WR. Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am J Surg Pathol 1995; 19: 66674.
  • 43
    Costa MJ, Vogelsang J, Young LJT. p53 gene mutation in female genital tract carcinosarcomas (malignant mixed muüllerian tumors): a clinicopathologic study of 74 cases. Mod Pathol 1994; 7: 61927.
  • 44
    Costa MJ, Kenny M, Judd R. Uterine glandular carcinoma. Correlation of histologic classification, immunohistochem-istry and grading with origin and outcome. Int J Surg Pathol 1993; 1: 1324.
  • 45
    Taylor CR, Shi SR, Chaiwun B, Young L, Imam SA, Cote RJ. Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin section: androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen and Ki67 antigen revealed by antigen retrieval techniques. Hum Pathol 1994; 25: 26370.
  • 46
    De Potter CR, Quatacker J, Maertens G, Van Daele S, Pauwels C, Verhofstede C, et al. The subcellular localization of the neu-protein in human normal and neoplastic cells. Int J Cancer 1989; 44: 96974.
  • 47
    Duncan RC, Knapp RG, Duncan RC. Introductory statistics for the health sciences. New York: John Wiley, 1977.
  • 48
    Duda RB, Cundiff D, August CZ, Wagman LD, Bauer KD. Growth factor receptor and related oncogene determination in mesenchymal tumors. Cancer 1993; 71: 352630.